Where can I find ROSGQ's financial statements?

Rosetta Genomics Ltd. (ROSGQ)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for ROSGQ?

Rosetta Genomics Ltd. (ROSGQ) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does ROSGQ update its statements?

Rosetta Genomics Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

ROSGQ

Rosetta Genomics Ltd.

OTC·Medical, Diagnostics & Research · Healthcare

$0.00$0.00+0.00%

Market cap$593.00·Market closed·Aug 26 8:00 PM UTC

USD · values shown as reported

Line item	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016
Revenue	$201.00K+95.1%	$405.00K+101.5%	$1.33M+227.7%	$8.27M+523.1%	$9.23M+11.7%
Cost of revenue	$258.00K−20.4%	$709.00K+174.8%	$1.31M+84.8%	$6.27M+378.8%	$7.44M+18.6%
Gross profit	−$57.00K+74.2%	−$304.00K−433.3%	$17.00K+105.6%	$2.00M+11,641.2%	$1.80M−10.1%
Research & development	$1.25M−63.2%	$1.74M+39.9%	$1.93M+10.5%	$2.96M+53.4%	$3.16M+6.8%
General & administrative	$3.03M+19.2%	$4.30M+42.0%	$5.49M+27.9%	$7.57M+37.7%	$7.50M−0.9%
Selling & marketing	$3.94M+49.6%	$7.00M+77.8%	$6.85M−2.2%	$7.35M+7.3%	$6.81M−7.4%
SG&A (combined)	$6.96M+34.7%	$11.30M+62.3%	$12.34M+9.2%	$14.92M+20.9%	$14.30M−4.1%
Other operating expenses	—	—	—	−$155.00K	—
Total operating expenses	$8.21M−4.0%	$13.04M+58.9%	$14.27M+9.4%	$17.72M+24.2%	$17.46M−1.5%
Operating income	−$8.27M+5.8%	−$13.35M−61.4%	−$14.25M−6.8%	−$15.72M−10.3%	−$15.66M+0.4%
Interest income	$39.00K+225.0%	$146.00K+274.4%	$111.00K−24.0%	$46.00K−58.6%	$10.00K−78.3%
Interest expense	$1.87M+9,721.1%	$15.00K−99.2%	$39.00K+160.0%	$48.00K+23.1%	$43.00K−10.4%
Other income / (expense), net	−$2.43M−275.5%	$177.00K+107.3%	−$259.00K−246.3%	−$1.61M−519.7%	−$603.00K+62.4%
Income before tax	−$10.70M−44.7%	−$13.17M−23.1%	−$14.51M−10.2%	−$17.33M−19.4%	−$16.27M+6.1%
Income tax expense	—	—	$15.00K	$19.00K+26.7%	−$34.00K−278.9%
Net income	−$10.46M−18.4%	−$12.90M−23.3%	−$14.53M−12.6%	−$17.35M−19.4%	−$16.23M+6.4%

EPS (basic)	−$28.20+86.5%	−$16.08+43.0%	−$15.51+3.5%	−$13.79+11.1%	−$9.31+32.5%
EPS (diluted)	−$28.20+86.5%	−$16.08+43.0%	−$15.51+3.5%	−$13.79+11.1%	−$9.31+32.5%
Weighted avg shares (basic)	370,704	799,495	936,657	1,257,723	1,743,067
Weighted avg shares (diluted)	370,704	799,495	936,657	1,257,723	1,743,067

Depreciation & amortization	$274.00K−40.2%	$298.00K+8.8%	$299.00K+0.3%	$748.00K+150.2%	$904.00K+20.9%
EBITDA	−$7.99M−15.6%	−$12.87M−61.0%	−$14.17M−10.1%	−$16.53M−16.6%	−$15.32M+7.3%

Frequently Asked Questions About ROSGQ

Where can I find ROSGQ's financial statements?: Rosetta Genomics Ltd. (ROSGQ)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for ROSGQ?: Rosetta Genomics Ltd. (ROSGQ) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does ROSGQ update its statements?: Rosetta Genomics Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2012

FY 2013

FY 2014

FY 2015

FY 2016

Trend

Revenue

$201.00K+95.1%

$405.00K+101.5%

$1.33M+227.7%

$8.27M+523.1%

$9.23M+11.7%

Cost of revenue

$258.00K−20.4%

$709.00K+174.8%

$1.31M+84.8%

$6.27M+378.8%

$7.44M+18.6%

Gross profit

−$57.00K+74.2%

−$304.00K−433.3%

$17.00K+105.6%

$2.00M+11,641.2%

$1.80M−10.1%

Research & development

$1.25M−63.2%

$1.74M+39.9%

$1.93M+10.5%

$2.96M+53.4%

$3.16M+6.8%

General & administrative

$3.03M+19.2%

$4.30M+42.0%

$5.49M+27.9%

$7.57M+37.7%

$7.50M−0.9%

Selling & marketing

$3.94M+49.6%

$7.00M+77.8%

$6.85M−2.2%

$7.35M+7.3%

$6.81M−7.4%

SG&A (combined)

$6.96M+34.7%

$11.30M+62.3%

$12.34M+9.2%

$14.92M+20.9%

$14.30M−4.1%

Other operating expenses

—

−$155.00K

—

Total operating expenses

$8.21M−4.0%

$13.04M+58.9%

$14.27M+9.4%

$17.72M+24.2%

$17.46M−1.5%

Operating income

−$8.27M+5.8%

−$13.35M−61.4%

−$14.25M−6.8%

−$15.72M−10.3%

−$15.66M+0.4%

Interest income

$39.00K+225.0%

$146.00K+274.4%

$111.00K−24.0%

$46.00K−58.6%

$10.00K−78.3%

Interest expense

$1.87M+9,721.1%

$15.00K−99.2%

$39.00K+160.0%

$48.00K+23.1%

$43.00K−10.4%

Other income / (expense), net

−$2.43M−275.5%

$177.00K+107.3%

−$259.00K−246.3%

−$1.61M−519.7%

−$603.00K+62.4%

Income before tax

−$10.70M−44.7%

−$13.17M−23.1%

−$14.51M−10.2%

−$17.33M−19.4%

−$16.27M+6.1%

Income tax expense

—

$15.00K

$19.00K+26.7%

−$34.00K−278.9%

Net income

−$10.46M−18.4%

−$12.90M−23.3%

−$14.53M−12.6%

−$17.35M−19.4%

−$16.23M+6.4%

EPS (basic)

−$28.20+86.5%

−$16.08+43.0%

−$15.51+3.5%

−$13.79+11.1%

−$9.31+32.5%

EPS (diluted)

−$28.20+86.5%

−$16.08+43.0%

−$15.51+3.5%

−$13.79+11.1%

−$9.31+32.5%

Weighted avg shares (basic)

370,704

799,495

936,657

1,257,723

1,743,067

Weighted avg shares (diluted)

370,704

799,495

936,657

1,257,723

1,743,067

Depreciation & amortization

$274.00K−40.2%

$298.00K+8.8%

$299.00K+0.3%

$748.00K+150.2%

$904.00K+20.9%

EBITDA

−$7.99M−15.6%

−$12.87M−61.0%

−$14.17M−10.1%

−$16.53M−16.6%

−$15.32M+7.3%